Joshua Richter: Another myeloma approval today! Elrexfio

In a post by Joshua Richter, Associate Professor of Medicine at Mount Sinai, it says:

“Another myeloma approval today! Elrexfio.
On August 14, 2023, the Food and Drug Administration granted accelerated approval to elranatamab-bcmm (Elrexfio, Pfizer, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.”

Read more here: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elrexfiotm-receives-us-fda-accelerated-approval

Source: Joshua Richter / Twitter